Q3 EPS Estimate for Bio-Rad Laboratories Cut by Analyst

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research cut their Q3 2025 earnings estimates for Bio-Rad Laboratories in a note issued to investors on Thursday, March 6th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.72 for the quarter, down from their previous estimate of $2.94. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.09 EPS, Q4 2026 earnings at $3.22 EPS, FY2026 earnings at $12.34 EPS and FY2027 earnings at $9.27 EPS.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%.

A number of other equities analysts have also recently commented on BIO. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $395.20.

Bio-Rad Laboratories Stock Performance

BIO opened at $258.37 on Friday. Bio-Rad Laboratories has a fifty-two week low of $248.22 and a fifty-two week high of $387.99. The stock has a market capitalization of $7.24 billion, a price-to-earnings ratio of -3.97 and a beta of 0.98. The company has a fifty day moving average of $322.58 and a 200 day moving average of $331.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors have recently made changes to their positions in BIO. Venturi Wealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after acquiring an additional 87 shares during the last quarter. GeoWealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter worth about $32,000. Picton Mahoney Asset Management lifted its holdings in shares of Bio-Rad Laboratories by 55.6% in the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock worth $32,000 after acquiring an additional 35 shares during the last quarter. Finally, Asset Planning Inc bought a new stake in shares of Bio-Rad Laboratories in the 4th quarter worth about $33,000. Institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.